Lacosamide UCB



This medicine is authorised for use in the European Union.


Lacosamide UCB is an epilepsy medicine used to treat partial-onset seizures (epileptic fits starting in one specific part of the brain) in patients with epilepsy aged 4 years or older. It can be used to treat partial-onset seizures with or without secondary generalisation (where the seizure subsequently spreads to other parts of the brain).

Lacosamide UCB is given on its own or combined with other medicines for epilepsy. It contains the active substance lacosamide.

This medicine is the same as Vimpat, which is already authorised in the EU. The company that makes Vimpat has agreed that its scientific data can be used for Lacosamide UCB (‘informed consent’).

This EPAR was last updated on 12/09/2019

Authorisation details

Product details
Lacosamide UCB
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Epilepsies, Partial
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
UCB Pharma S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Allée de la Recherche 60
B-1070 Bruxelles

Product information

Lacosamide UCB - EMEA/H/C/005243 -


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Assessment history

How useful was this page?

Add your rating